ZURICHDrug companies are back in deal mode On Tuesday Novartis AG and GlaxoSmithKline PLC unveiled a series of transactions worth more than  billion that fundamentally transform both companies more tightly focusing Novartiss scope without significantly crimping its revenue while turning Glaxo into a vaccinesandconsumerdrug powerhouse The
  